The application of prostate-specific antigen(PSA) in the screening and diagnosis of prostate cancer(PCa) has improved the clinical management of PCa patients. However, the PSA assay has been faced with criticism d...The application of prostate-specific antigen(PSA) in the screening and diagnosis of prostate cancer(PCa) has improved the clinical management of PCa patients. However, the PSA assay has been faced with criticism due to its potential association with over-diagnosis and subsequent overtreatment of indolent patients. Matrix metalloproteinase-26(MMP26) is a member of matrix metalloproteinases(MMPs) and has been reported to be highly expressed in many cancers. This investigation evaluated the potential of serum MMP26 as a biomarker for PCa. The level of serum MMP26 was measured by enzyme-linked immunosorbent assay(ELISA) in 160 subjects including PCa group(n=80), benign prostatic hyperplasia(BPH) group(n=40) and control group(n=40). Furthermore, we evaluated the expression of MMP26 in tissues by immunohistochemistry. The results showed the serum MMP26 levels were significantly higher in PCa group than in BPH group and control group. Similarly, the MMP26 protein was positive in PCa tissues and negative in BPH tissues and control tissues. In conclusion, these results suggested MMP26 could be used as a potential serum biomarker in the diagnosis of PCa.展开更多
文摘目的 应用性染色体双色间期荧光原位杂交技术检测异性间造血干细胞移植后,患者的嵌合状态,并对其应用价值进行分析.方法 对2006年1月~2007年12月在天津血液病医院行异性间allo-HSCT的32例患者,常规染色体核型分析采用不加任何刺激剂的骨髓24 h短期培养法制备染色体,火焰法滴片,R显带.应用X/Y性染色体双色着丝粒DNA探针对骨髓间期细胞行荧光原位杂交,检测移植后患者的嵌合状态.结果 32例患者染色体核型分析115例次,其中111例次为正常供者核型,1例次受者核型,3例次分析失败,未能检测到混合核型.双色性染色体间期FISH检测163例次,129例次为完全嵌合,34例次为混合嵌合,检测成功率为100%.移植后2~3 w 32.2%患者为混合状态,移植后1 mo 76.7%患者为完全嵌合,移植后半年94.1%患者为完全嵌合.结论 性染色体双色间期荧光原位杂交能够简便、快速、灵敏地检测出异性间allo-HSCT患者移植后的嵌合状态.
基金supported by grants from the National Nature Science Foundations of China(No.81372801,No.81472783,No.81630060,No.81230083 and No.81272422)the National Basic Research Program of China(No.2015CB553003)
文摘The application of prostate-specific antigen(PSA) in the screening and diagnosis of prostate cancer(PCa) has improved the clinical management of PCa patients. However, the PSA assay has been faced with criticism due to its potential association with over-diagnosis and subsequent overtreatment of indolent patients. Matrix metalloproteinase-26(MMP26) is a member of matrix metalloproteinases(MMPs) and has been reported to be highly expressed in many cancers. This investigation evaluated the potential of serum MMP26 as a biomarker for PCa. The level of serum MMP26 was measured by enzyme-linked immunosorbent assay(ELISA) in 160 subjects including PCa group(n=80), benign prostatic hyperplasia(BPH) group(n=40) and control group(n=40). Furthermore, we evaluated the expression of MMP26 in tissues by immunohistochemistry. The results showed the serum MMP26 levels were significantly higher in PCa group than in BPH group and control group. Similarly, the MMP26 protein was positive in PCa tissues and negative in BPH tissues and control tissues. In conclusion, these results suggested MMP26 could be used as a potential serum biomarker in the diagnosis of PCa.